Timothy Cowper
Financieel Directeur/CFO bij VERNALIS
Vermogen: 229 252 $ op 30-04-2024
Profiel
Momenteel is Tim Cowper Chief Financial Officer & Director bij Oxford Nanopore Technologies Ltd. en Financieel Directeur voor Vernalis Ltd. De heer Cowper bekleedde voordien de functie van financieel controleur voor Celltech Group Plc.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 11-04-2024 | 186 158 ( 0.02% ) | 229 252 $ | 30-04-2024 |
Actieve functies van Timothy Cowper
| Bedrijven | Functie | Begin |
|---|---|---|
| OXFORD NANOPORE TECHNOLOGIES PLC | Operationeel Directeur | 22-01-2024 |
| VERNALIS | Financieel Directeur/CFO | - |
Eerdere bekende functies van Timothy Cowper
| Bedrijven | Functie | Einde |
|---|---|---|
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Comptroller/Controller/Auditor | 01-01-1997 |
| Sterilox Medical Ltd. | Comptroller/Controller/Auditor | - |
Opleiding van Timothy Cowper
| University of Sussex | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| OXFORD NANOPORE TECHNOLOGIES PLC | Electronic Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
| Sterilox Medical Ltd. |
